Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In addition to DNA methylation, reversible epigenetic modification occurring in RNA has been discovered recently. The most abundant type of RNA methylation is N6-methyladenosine (m6A) modification, which is dynamically regulated by methylases ("writers"), demethylases ("erasers") and m6A-binding proteins ("readers"). As an essential posttranscriptional regulator, m6A can control mRNA splicing, processing, stability, export and translation. Recent studies have revealed that m6A modification has the strongest tissue specificity for brain tissue and plays crucial roles in central nervous system (CNS) injures by affecting its downstream target genes or non-coding RNAs. This review focuses on the expression and function of m6A regulatory proteins in CNS trauma in vitro and in vivo. We also highlight the latest insights into the molecular mechanisms of pathological damage in the CNS. Understanding m6A dynamics, functions, and machinery will yield an opportunity for designing and developing novel therapeutic agents for CNS injuries.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.expneurol.2021.113829 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Changes in pH and myelin-related proteins expression in neonatal pigs post-hypoxic-ischemic injury.
J Neurophysiol
September 2025
Department of Radiology, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Heping District, Shenyang 110004, China.
Neonatal hypoxic-ischemic encephalopathy (HIE) is a significant cause of developmental disorders and permanent central nervous system damage, with functional recovery closely linked to myelin sheath integrity. This study aimed to analyze the expression of pH and the voltage-gated proton channel (Hv1) in the brains of neonatal pigs with HIE at various time points, alongside changes in myelin-related proteins. MRI was employed to localize the basal ganglia and assess pH changes post-hypoxia-ischemia, while immunofluorescence staining was used to evaluate Hv1, myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and myelin-associated glycoprotein (MAG).
View Article and Find Full Text PDFHuman myelinated brain organoids with integrated microglia as a model for myelin repair and remyelinating therapies.
Sci Transl Med
September 2025
Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Oligodendrocytes, the myelinating cells of the central nervous system (CNS), are essential for the formation of myelin sheaths and pivotal for maintaining axonal integrity and conduction. Disruption of these cells and the myelin sheaths they produce is a hallmark of demyelinating conditions like multiple sclerosis or those resulting from certain drug side effects, leading to profound neurological impairments. In this study, we created a human brain organoid comprising neurons, astrocytes, and myelinating oligodendrocytes.
View Article and Find Full Text PDFType I interferon limits central nervous system autoimmunity by modulating the microRNA-21-FOXO1 axis in pathogenic T helper 17 cells.
Sci Transl Med
September 2025
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
IFN-β, a type I interferon, has been used as a first-line therapy for patients with multiple sclerosis (MS) for more than 30 years; however, the cellular and molecular basis of its therapeutic efficacy remains unclear. Here, we first used experimental autoimmune encephalomyelitis (EAE), a mouse model for MS, to show that the therapeutic effects of IFN-β were associated with a down-regulation of microRNA-21 (miR-21) and pathogenic T17 (pT17) cells. In vitro experiments demonstrated that genetic knockout of miR-21 directly inhibited pathogenic T17 cell differentiation.
View Article and Find Full Text PDFNano-Chinese herbal medicines and their delivery strategies for central nervous system disease therapy.
Nanoscale Horiz
September 2025
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing 100190, China.
Central nervous system (CNS) diseases, including neurodegenerative diseases, stroke, brain tumors, and others, result in poor quality of life and can cause substantial disability. Not all CNS diseases are amenable to surgical approaches, so drug development is important for disease treatment. Unfortunately, there are few drugs currently available for CNS diseases.
View Article and Find Full Text PDFCK2 derived from brain microvascular endothelial cells induces astrocyte inflammatory response in Escherichia coli-induced meningitis.
PLoS Pathog
September 2025
National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.
Neuroinflammation within the central nervous system (CNS) is recognized as a critical pathological process in meningitic Escherichia coli (E. coli) infection, leading to severe neurodegenerative disorders and long-term sequelae. Astrocyte reactivity plays a pivotal role in driving the neuroinflammatory cascade in response to pathological stimuli from peripheral sources or other cellular components of the CNS.
View Article and Find Full Text PDF